Taxotere data

Taxotere, a taxol alternative made by RPR, gave an average tumor response of 31 percent in four Phase II lung cancer trials, reducing tumor size at least 50 percent in 11 of 29 patients in one of the trials, conducted by Memorial Sloan-Kettering Cancer Center.

As presented at the World Conference on Lung Cancer in Colorado Springs, the reduction in tumor size by taxotere in 38 percent of patients with non-small cell lung cancer contrasts with a typical response rate of 10 to 20 percent with single-agent chemotherapy. ...